Anti-PD1 antibody, nimotuzumab and capecitabine
Phase 2Small molecule
Anti-PD1 antibody, nimotuzumab and capecitabine is one of 37 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
282 competitors in Nasopharyngeal Carcinoma
#DrugCompanyPhaseTrials
1Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Tuoyi
SSun Yat-sen University
Phase 3
Erbitux
IImclone
Phase 3
Paraplatin
AAvyxa
Phase 3
Adrucil
EElorac, Inc.
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Zovirax
BBp Consulting, Inc
Phase 3
Celebrex
PPhiladelphia Eye Associates
Phase 3
Gemcitabine/cisplatin
AstraZenecaPhase 3
Albumin-Bound Paclitaxel
Bristol-Myers SquibbPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details